Glycated hemoglobin (HbA1c) trajectories among children during the first 5 years after diagnosis of type 1 diabetes, stratified by diagnostic era and diagnostic.

Slides:



Advertisements
Similar presentations
Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.
Advertisements

The prevalence of diabetes (A), impaired glucose tolerance (B), impaired fasting glucose (C), and impaired glucose metabolism (D) among those with Finnish.
Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.
Differences in the glycated hemoglobin (HbA1c) levels.
Predicted and observed HbA1c levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)
Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.
Illustration of the causal inference scheme.
Patient flow chart: the final prospective study population consisted of 521 individuals, 113 on basal insulin and 408 on OADs. *Plausibility: height (130–230 cm),
DASH component score by Hispanic/Latino heritage adjusted by age and sex. 1Adjusted by age and sex (mean age: 41.07, % male: 47.71). 2Each component ranges.
Screening, enrollment, and randomization of study participants (BMI, body mass index; CTG, conventional therapy group; HbA1c, glycated hemoglobin; HDL-C,
Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.
Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.
Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.
Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.
Estimated HR as a function of absolute change in glycated hemoglobin (HbA1c; from index to measurement 22–26 months after). Estimated HR as a function.
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.
Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.
Mathematical modeling of bubble formation in insulin pump cartridges (3 mL solid line, 2 mL dotted line, and 1.8 mL dashed line) and lines during an increase.
Changes over time in (A) waist circumference, (B) BMI, (C) ALT, (D) Matsuda index, (E) AUCglucagon, and (F) ISSI-2, comparing patients with drug-free diabetes.
Intensity of statin treatment and possible lipid lowering treatment intolerance and/or ineffectiveness issues among patients with type 2 diabetes (aged.
Geographic areas with increased ED visits after Hurricane Sandy by diabetic adults. Geographic areas with increased ED visits after Hurricane Sandy by.
Change in HbA1c and weight compared with baseline variables for the liraglutide group and the placebo group. Change in HbA1c and weight compared with baseline.
(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.
Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.
Receiver operating characteristic analyses showing area under the curves with reference to 2-hour OGTT (A,B) and fasting plasma glucose (C,D). HbA1c, glycated.
Scatterplot showing the association between baseline weight and weight change at 1 year, relative to baseline for each treatment group. Scatterplot showing.
Scatterplot showing the association between change in HbA1c at 1 year and weight change at 1 year, relative to baseline for each treatment group. Scatterplot.
Calibration plot by quintiles of predicted 5-year diabetes risk of the comprehensive German Diabetes Risk Score (GDRS) for prediction of incident diagnosed.
Adjusted annual percentage of quality indicators by prescription
Age-standardized probability of finding undiagnosed diabetes among the US population without diagnosed diabetes aged ≥18 years by survey cycle. Age-standardized.
Subgroup analysis of physical activity rates—Asian immigrants versus whites stratified by DM status. Subgroup analysis of physical activity rates—Asian.
(A) Rate of achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in all subjects and (B) prevalence of nephropathy, retinopathy,
(A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group). (A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group).
Adjusted OR and SE for BMI≥30 kg/m2, BMI 25–29. 9 kg/m2, HbA1c≥6
Inclusion process. Inclusion process. Of 5200 eligible patients, 204 declined participation, 111 had diabetes >400 days before All New Diabetics in Scania.
Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.
Mean and interquartile glucose values for (A) random blood glucose, (B) fastingplasma glucose, (C) HbA1c, (D) 1-hour OGTT, (E) 2-hour OGTT and (F)triglycerides.
Comparison of receiver operating characteristic (ROC) curves for predicting oral glucose tolerance test (OGTT) 1 h postload glucose ≥155 mg/dL in (A) patients.
Estimated HR as a function of mean residual of glycated hemoglobin (HbA1c) measurements to the line connecting index HbA1c and HbA1c measurement 22–26 months.
Association between antibiotic purchases and glycated hemoglobin (HbA1c) values in patients with and without diabetic nephropathy. Association between.
Enrollment of patients.
Hypothesized causal relations between exposures (education, immigration and income) and outcome (HbA1c at diagnosis). Hypothesized causal relations between.
(A–B) Differences in fat oxidation during the hyperinsulinemic euglycemic clamp between African–American and non-Hispanic white women after 7 days of a.
Relationships between annual antibiotic purchase rates and progression of microalbuminuria in patients with type 1 diabetes. Relationships between annual.
Final model of factors for diabetes in the STEPwise approach to surveillance 2012 survey—Qatar among adults aged 18–64 years. Final model of factors for.
Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),
(A) Glucose values (mean +SEM) during continuous glucose monitoring while consuming whey protein (solid lines and filled circles) or placebo (broken lines.
Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.
Change in markers of glycometabolism and cardiovascular risk profile.
Interaction of updated mean serial HbA1c and serum triglyceride levels with sensory peripheral neuropathy over 7 years in 151 type 2 diabetic participants.
Participant flow diagram for the ‘GNHIES98—longitudinal sample’ and the ‘DEGS1—cross-sectional sample’. Participant flow diagram for the ‘GNHIES98—longitudinal.
Associations of body mass index (BMI) levels with achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in the upper panels.
Continuous associations
Continuous associations
Percentage of weight loss over 5 years in response to 12-week intensive lifestyle intervention in a real-world clinical practice. Percentage of weight.
Oral glucose tolerance testing during hospitalization and at 4 months after infarction. Oral glucose tolerance testing during hospitalization and at 4 months.
Insulin sensitivity (Si-clamp) in obese and non-obese study subjects (A) and cumulative incidence of pre-diabetes/type 2 diabetes in insulin-resistant.
Trajectories over the 9 years of follow-up of HbA1c in all participants (n = 4,080 at baseline), stratified by the presence of a family history of diabetes,
Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.
Crude and adjusted HbA1c change by medication adherence group (proportion of days covered (PDC)) by linear regression, controlling for age, age2, gender,
Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.
Changes (means±posterior SDs) in HbA1c (A), fasting glucose (B), and body weight (C) by treatment condition based on missing not at random (MNAR) analyses.
This figure shows the inclusion and exclusion criteria used to derive the final analytic cohort of 2563 persons with diabetes from the initial 4915 persons.
Adjusted OR and SE for BMI≥30 kg/m2, BMI 25–29. 9 kg/m2, HbA1c≥6
Plasma glucose (A), serum insulin (B), serum C peptide (C) and plasma GLP-1 level (D) during the 2-hour OGTT among subjects with normal glucose tolerance.
Postprandial glucose, insulin and glucagon-like peptide-1 (GLP-1) levels following carbohydrate-first (CF), carbohydrate-last (CL) and sandwich (S) meal.
Patient disposition and study protocol.
Trends in age-adjusted diagnosed diabetes prevalence and incidence among adults aged 18–79 years, 1980–2017. Trends in age-adjusted diagnosed diabetes.
Presentation transcript:

Glycated hemoglobin (HbA1c) trajectories among children during the first 5 years after diagnosis of type 1 diabetes, stratified by diagnostic era and diagnostic age (A), and by initial HbA1c after the initiation of insulin therapy (B). Glycated hemoglobin (HbA1c) trajectories among children during the first 5 years after diagnosis of type 1 diabetes, stratified by diagnostic era and diagnostic age (A), and by initial HbA1c after the initiation of insulin therapy (B). (A) HbA1c trajectories by diagnostic age for individuals diagnosed before 2000 (left), 2000–2003 (middle), and 2004–2009 (right). A p<0.0001 for diagnostic era×diagnostic age interaction. (B) HbA1c trajectories by diagnostic age for individuals with initial HbA1c after initiation of insulin therapy <7% (<53 mmol/mol; left), 7–9% (53–75 mmol/mol; middle), or >9% (>75 mmol/mol; right). A p<0.0001 for initial A1c×diagnostic age interaction (B). Solid line=age at diagnosis 0–4 years, dashed line=age at diagnosis 5–9 years, and dotted line=age at diagnosis ≥10 years. Mark A Clements et al. BMJ Open Diab Res Care 2014;2:e000039 ©2014 by American Diabetes Association